$QRON
Qrons Inc.

2022 Q2 Form 10-Q Financial Statement

#000147793222003460 Filed on May 16, 2022

View on sec.gov

Income Statement

Concept 2022 Q2 2022 Q1 2021 Q4
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $22.65K $54.62K $464.5K
YoY Change -27.98% 105.88%
% of Gross Profit
Research & Development $8.414K $8.932K $226.0K
YoY Change -25.87% -24.54%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $31.06K $63.56K $690.5K
YoY Change -27.42% 65.67%
Operating Profit -$31.06K -$63.56K
YoY Change -27.42% 65.67%
Interest Expense $27.91K $34.62K -$96.88K
YoY Change -75.02% 215.1%
% of Operating Profit
Other Income/Expense, Net $102.7K -$200.6K
YoY Change 32.78% 1.84%
Pretax Income $71.67K -$264.1K -$787.4K
YoY Change 107.32% 12.25%
Income Tax
% Of Pretax Income
Net Earnings $71.67K -$264.1K -$787.4K
YoY Change 107.3% 12.25%
Net Earnings / Revenue
Basic Earnings Per Share $0.01
Diluted Earnings Per Share $0.00 -$19.87K -$59.25K
COMMON SHARES
Basic Shares Outstanding 13.29M shares
Diluted Shares Outstanding 18.76M shares

Balance Sheet

Concept 2022 Q2 2022 Q1 2021 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $8.350K $5.650K $35.07K
YoY Change -90.1% -80.81%
Cash & Equivalents $8.354K $5.654K $35.07K
Short-Term Investments
Other Short-Term Assets $2.160K
YoY Change -64.0%
Inventory
Prepaid Expenses $2.163K $0.00
Receivables
Other Receivables
Total Short-Term Assets $8.354K $7.820K $35.07K
YoY Change -90.55% -77.93% -39.16%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $0.00 $0.00 $0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets $8.354K $7.820K $35.07K
Total Long-Term Assets $0.00 $0.00 $0.00
Total Assets $8.354K $7.820K $35.07K
YoY Change -90.55% -77.93% -39.16%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $156.3K $170.8K $129.2K
YoY Change 49.62% 58.07%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $436.0K $386.0K $386.0K
YoY Change 12.95% 0.0%
Long-Term Debt Due $270.0K $246.0K $216.7K
YoY Change 91.31% 92.97%
Total Short-Term Liabilities $1.304M $1.375M $1.138M
YoY Change 33.39% 42.9% 51.31%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $1.304M $1.375M $1.138M
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $1.304M $1.375M $1.138M
YoY Change 33.39% 42.9% 51.31%
SHAREHOLDERS EQUITY
Retained Earnings -$8.994M -$8.801M
YoY Change 13.81%
Common Stock $1.329K $1.329K
YoY Change 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$1.295M -$1.367M -$1.103M
YoY Change
Total Liabilities & Shareholders Equity $8.354K $7.820K $35.07K
YoY Change -90.55% -77.93% -39.16%

Cashflow Statement

Concept 2022 Q2 2022 Q1 2021 Q4
OPERATING ACTIVITIES
Net Income $71.67K -$264.1K -$787.4K
YoY Change 107.3% 12.25%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$47.30K -$29.41K -$22.11K
YoY Change 4.97% 4.34%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00 $0.00
YoY Change
Cash From Investing Activities $0.00 $0.00 $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 50.00K $0.00 0.000
YoY Change -50.0%
NET CHANGE
Cash From Operating Activities -47.30K -$29.41K -22.11K
Cash From Investing Activities 0.000 $0.00 0.000
Cash From Financing Activities 50.00K $0.00 0.000
Net Change In Cash 2.700K -$29.41K -22.11K
YoY Change -95.09% 4.34%
FREE CASH FLOW
Cash From Operating Activities -$47.30K -$29.41K -$22.11K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q1 us-gaap Revenues
Revenues
0 USD
CY2022Q1 us-gaap Operating Expenses
OperatingExpenses
63556 USD
CY2021Q1 us-gaap Operating Expenses
OperatingExpenses
38363 USD
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-63556 USD
CY2021Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-38363 USD
CY2022Q1 us-gaap Interest Expense
InterestExpense
34617 USD
CY2021Q1 us-gaap Interest Expense
InterestExpense
10986 USD
CY2022Q1 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-165955 USD
CY2021Q1 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-185960 USD
CY2022Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-200572 USD
CY2021Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-196946 USD
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-264128 USD
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-235309 USD
CY2022Q1 qron Earnings Loss Per Share Basic And Diluted
EarningsLossPerShareBasicAndDiluted
-0.02
CY2021Q1 qron Earnings Loss Per Share Basic And Diluted
EarningsLossPerShareBasicAndDiluted
-0.02
CY2022Q1 qron Weighted Average Number Of Common Share Outstanding Basic And Diluted
WeightedAverageNumberOfCommonShareOutstandingBasicAndDiluted
13289789 shares
CY2021Q1 qron Weighted Average Number Of Common Share Outstanding Basic And Diluted
WeightedAverageNumberOfCommonShareOutstandingBasicAndDiluted
13289789 shares
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-1102745 USD
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-264128 USD
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
-1366873 USD
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-694316 USD
CY2021Q1 qron Issued During Period Value Options Granted To Non Employee
IssuedDuringPeriodValueOptionsGrantedToNonEmployee
3100 USD
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-235309 USD
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
-926525 USD
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-264128 USD
CY2022Q1 us-gaap Stock Option Plan Expense
StockOptionPlanExpense
0 USD
CY2021Q1 us-gaap Stock Option Plan Expense
StockOptionPlanExpense
3100 USD
CY2022Q1 us-gaap Accretion Expense
AccretionExpense
29291 USD
CY2021Q1 us-gaap Accretion Expense
AccretionExpense
8833 USD
CY2022Q1 us-gaap Increase Decrease In Derivative Liabilities
IncreaseDecreaseInDerivativeLiabilities
165955 USD
CY2021Q1 us-gaap Increase Decrease In Derivative Liabilities
IncreaseDecreaseInDerivativeLiabilities
185960 USD
CY2022Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
2163 USD
CY2021Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
6000 USD
CY2022Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
41054 USD
CY2021Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
17623 USD
CY2022Q1 qron Increase Decrease In Accounts Payable And Accrued Liabilities Related Parties
IncreaseDecreaseInAccountsPayableAndAccruedLiabilitiesRelatedParties
580 USD
CY2021Q1 qron Increase Decrease In Accounts Payable And Accrued Liabilities Related Parties
IncreaseDecreaseInAccountsPayableAndAccruedLiabilitiesRelatedParties
-2396 USD
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-29411 USD
CY2021Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-28189 USD
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0 USD
CY2021Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0 USD
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
0 USD
CY2021Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
0 USD
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-29411 USD
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-28189 USD
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
35065 USD
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
57632 USD
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5654 USD
CY2021Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
29443 USD
CY2022Q1 us-gaap Interest Paid Net
InterestPaidNet
0 USD
CY2021Q1 us-gaap Interest Paid Net
InterestPaidNet
0 USD
CY2022Q1 us-gaap Income Taxes Paid
IncomeTaxesPaid
0 USD
CY2021Q1 us-gaap Income Taxes Paid
IncomeTaxesPaid
0 USD
CY2022Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
13289789 shares
CY2022Q1 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
2163 USD
CY2021Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
0 USD
CY2021 us-gaap Proceeds From Loans
ProceedsFromLoans
100000 USD
CY2020 us-gaap Proceeds From Loans
ProceedsFromLoans
211000 USD
CY2020 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
10000 USD
CY2022Q1 qron Licence Fee
LicenceFee
25000 USD
CY2022Q1 qron Annual License Fee
AnnualLicenseFee
25000 USD
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P3Y29D
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
2
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.98
CY2022Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2022Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
4098332 shares
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P3Y29D
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3276666 shares
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
1.98
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P3Y3M10D
CY2022Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0
CY2022Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
0
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
975000 shares
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
2
CY2022Q1 qron Share Based Compensation Arrangements By Share Based Payment Award Options Exercised In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageExercisePrice
0
CY2021 qron Share Based Compensation Arrangements By Share Based Payment Award Options Exercised In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageExercisePrice
0
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
153334 shares
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4098332 shares
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P2Y9M3D
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
4098332 shares
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
2
CY2021 qron Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Terms2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerms2
P3Y29D
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4098332 shares
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
2
CY2022Q1 qron Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Terms2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerms2
P2Y9M3D
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4098332 shares
CY2022Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000 shares
CY2022Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q2 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
1.00
CY2022Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
13289789 shares
CY2020 qron Share Based Compensation Arrangements By Share Based Payment Award Non Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice
1.00
CY2020Q4 qron Share Based Compensation Arrangements By Share Based Payment Award Non Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice
1.00
CY2022Q1 qron Share Based Compensation Arrangements By Share Based Payment Award Non Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice
0
CY2021Q4 qron Share Based Compensation Arrangements By Share Based Payment Award Non Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice
1.00
CY2021Q2 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
115000 shares
CY2020 qron Share Based Compensation Arrangements By Share Based Payment Award Non Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsForfeituresInPeriodWeightedAverageExercisePrice
0
CY2022Q1 qron Share Based Compensation Arrangements By Share Based Payment Award Non Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsForfeituresInPeriodWeightedAverageExercisePrice
0
CY2021Q4 qron Share Based Compensation Arrangements By Share Based Payment Award Non Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice
1.00
CY2020 qron Share Based Compensation Arrangements By Share Based Payment Award Non Options Exercised In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisedInPeriodWeightedAverageExercisePrice
0
CY2022Q1 qron Share Based Compensation Arrangements By Share Based Payment Award Non Options Exercised In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisedInPeriodWeightedAverageExercisePrice
0
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
295000 shares

Files In Submission

Name View Source Status
0001477932-22-003460-index-headers.html Edgar Link pending
0001477932-22-003460-index.html Edgar Link pending
0001477932-22-003460.txt Edgar Link pending
0001477932-22-003460-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
qron-20220331.xsd Edgar Link pending
qron-20220331_cal.xml Edgar Link unprocessable
qron-20220331_def.xml Edgar Link unprocessable
qron-20220331_lab.xml Edgar Link unprocessable
qron-20220331_pre.xml Edgar Link unprocessable
qron_10q.htm Edgar Link pending
qron_10q_htm.xml Edgar Link completed
qron_ex31.htm Edgar Link pending
qron_ex32.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending